|
|
Blood, 1 June 2004, Vol. 103, No. 11, pp. 4362-4364.
Prepublished online as a Blood First Edition Paper on February 19, 2004; DOI 10.1182/blood-2003-11-3862.
Submitted November 12, 2003
Accepted January 30, 2004
The occurrence of Graft versus Host Disease is the major predictive factor for Response to Donor Lymphocyte Infusions in Multiple Myeloma
Henk M Lokhorst*, Kalung Wu, Leo F Verdonck, Laurens L Laterveer, Niels W Van de Donk, Marinus H Oers, Jan J Cornelissen, and Anton V Schattenberg
Hematology, University Medical Center, Utrecht, The Netherlands
Hematology, University Medical Center, Rotterdam, The Netherlands
Hematology, University Medical Center, Amsterdam, The Netherlands
Hematology, University Medical Center, Nijmegen, The Netherlands
* Corresponding author; email: h.lokhorst{at}azu.nl.
The Graft versus Myeloma effect of Donor Lymphocyte Infusions (DLI) is well established. We now report the outcome of DLI in 54 patients with relapsed myeloma following allogeneic transplantation. Twenty-eight (52%) patients responded, 19 (35%)patients with a partial response and 9 patients (17 %) with a complete response. Progression free and overall survival were 19 and 23 months respectively. We found that acute and chronic Graft versus Host Disease (GVHD) observed in 57 % and 47 % of patients respectively following DLI were the strongest predictors for response. This suggests that targets for GVHD and GVM are identical. In a subgroup analysis deletion of chromosome 13, as determined by double color Fish, had no impact on outcome, indicating that these patients are candidates for early allogeneic transplant followed by DLI in case of insufficient response.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. P. Rapoport, E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H.-B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al.
Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells
Clin. Cancer Res.,
July 1, 2009;
15(13):
4499 - 4507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kolb
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Blood,
December 1, 2008;
112(12):
4371 - 4383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Crawley, S. Iacobelli, B. Bjorkstrand, J. F. Apperley, D. Niederwieser, G. Gahrton, and for the Chronic Leukaemia Working Party of the Eur
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Blood,
April 15, 2007;
109(8):
3588 - 3594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Lokhorst
No RIC in high-risk myeloma?
Blood,
May 1, 2006;
107(9):
3420 - 3421.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Garban, M. Attal, M. Michallet, C. Hulin, J. H. Bourhis, I. Yakoub-Agha, T. Lamy, G. Marit, F. Maloisel, C. Berthou, et al.
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
Blood,
May 1, 2006;
107(9):
3474 - 3480.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kroger, A. Shimoni, M. Zagrivnaja, F. Ayuk, M. Lioznov, H. Schieder, H. Renges, B. Fehse, T. Zabelina, A. Nagler, et al.
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
Blood,
November 15, 2004;
104(10):
3361 - 3363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson
Multiple Myeloma
Hematology,
January 1, 2004;
2004(1):
237 - 256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
